Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -11.43 Million AUD | -2.03% |
| 2023 | -11.2 Million AUD | -148.85% |
| 2022 | -7.2 Million AUD | 47.44% |
| 2021 | -7.15 Million AUD | -16.1% |
| 2020 | -5.87 Million AUD | -1.43% |
| 2019 | -6.4 Million AUD | -0.6% |
| 2018 | -6.09 Million AUD | 21.4% |
| 2017 | -7.79 Million AUD | 10.1% |
| 2016 | -8.43 Million AUD | 7.8% |
| 2015 | -8.54 Million AUD | 14.56% |
| 2014 | -9.39 Million AUD | -14.46% |
| 2013 | -8.92 Million AUD | -97.6% |
| 2012 | -5.25 Million AUD | -542.95% |
| 2011 | 1.06 Million AUD | -84.81% |
| 2010 | -9.7 Million AUD | 344.61% |
| 2009 | -4.25 Million AUD | -145.9% |
| 2008 | 6.27 Million AUD | 1350.99% |
| 2007 | 158.62 Thousand AUD | 111.07% |
| 2006 | -4.27 Million AUD | 37.23% |
| 2005 | -6.21 Million AUD | 18.23% |
| 2004 | -7.02 Million AUD | -803.49% |
| 2003 | -841.51 Thousand AUD | 82.41% |
| 2002 | -2.68 Million AUD | -13569.88% |
| 2001 | 35.51 Thousand AUD | 101.41% |
| 2000 | -2.51 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.44 Million AUD | 1.85% |
| 2024 FY | - AUD | -30.38% |
| 2024 Q2 | -4.88 Million AUD | 0.0% |
| 2024 Q3 | -2.58 Million AUD | -6.01% |
| 2024 Q4 | -2.58 Million AUD | 0.0% |
| 2023 FY | - AUD | -148.85% |
| 2023 Q1 | -2.53 Million AUD | 35.93% |
| 2023 Q3 | -2.48 Million AUD | 50.85% |
| 2023 Q4 | -4.23 Million AUD | -70.31% |
| 2023 Q2 | -5.06 Million AUD | -100.0% |
| 2022 Q3 | -1.79 Million AUD | 62.28% |
| 2022 Q2 | -4.75 Million AUD | -163.52% |
| 2022 Q4 | -3.94 Million AUD | -120.08% |
| 2022 FY | - AUD | 47.44% |
| 2022 Q1 | -1.8 Million AUD | 53.05% |
| 2021 Q2 | -4.3 Million AUD | -139.99% |
| 2021 Q1 | -1.79 Million AUD | 54.55% |
| 2021 FY | - AUD | -16.1% |
| 2021 Q4 | -3.84 Million USD | -115.51% |
| 2021 Q3 | -1.78 Million AUD | 58.54% |
| 2020 Q4 | -3.94 Million AUD | -67.58% |
| 2020 FY | - AUD | -1.43% |
| 2020 Q2 | -2.94 Million AUD | -126.28% |
| 2020 Q3 | -2.35 Million AUD | 20.04% |
| 2020 Q1 | -1.3 Million AUD | 60.3% |
| 2019 Q1 | -1.53 Million AUD | -8.65% |
| 2019 FY | - AUD | -0.6% |
| 2019 Q2 | -1.53 Million AUD | -0.0% |
| 2019 Q3 | -1.89 Million AUD | -23.33% |
| 2019 Q4 | -3.27 Million USD | -73.04% |
| 2018 Q4 | -1.41 Million AUD | 0.0% |
| 2018 FY | - AUD | 21.4% |
| 2018 Q2 | -1.63 Million AUD | -0.0% |
| 2018 Q1 | -1.63 Million AUD | 11.73% |
| 2018 Q3 | -1.41 Million AUD | 13.57% |
| 2017 Q4 | -1.85 Million AUD | 0.0% |
| 2017 Q3 | -1.85 Million AUD | 5.38% |
| 2017 Q2 | -1.95 Million AUD | 0.0% |
| 2017 Q1 | -1.95 Million AUD | 7.24% |
| 2017 FY | - AUD | 10.1% |
| 2016 Q4 | -2.11 Million AUD | 0.0% |
| 2016 Q2 | -1.94 Million AUD | 0.0% |
| 2016 Q1 | -1.94 Million AUD | 5.02% |
| 2016 Q3 | -2.11 Million AUD | -8.8% |
| 2016 FY | - AUD | 7.8% |
| 2015 FY | - AUD | 14.56% |
| 2015 Q4 | -2.04 Million AUD | 0.0% |
| 2015 Q3 | -2.04 Million AUD | 26.34% |
| 2015 Q2 | -2.77 Million AUD | 0.0% |
| 2015 Q1 | -2.77 Million AUD | -17.08% |
| 2014 Q4 | -2.36 Million AUD | 0.0% |
| 2014 FY | - AUD | -14.46% |
| 2014 Q2 | -2.56 Million AUD | 0.0% |
| 2014 Q1 | -2.56 Million AUD | 3.79% |
| 2014 Q3 | -2.36 Million AUD | 7.73% |
| 2013 Q1 | -1.79 Million AUD | 0.0% |
| 2013 FY | - AUD | -97.6% |
| 2013 Q3 | -2.66 Million AUD | -48.65% |
| 2013 Q2 | -1.79 Million AUD | 0.0% |
| 2013 Q4 | -2.66 Million AUD | 0.0% |
| 2012 FY | - AUD | -542.95% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | - AUD | -84.81% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 344.61% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | -145.9% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | - AUD | 1350.99% |
| 2008 Q1 | 4.42 Million AUD | 149.16% |
| 2008 Q2 | 1.29 Million AUD | -70.8% |
| 2008 Q4 | -14.35 Million AUD | -316.43% |
| 2008 Q3 | 6.63 Million AUD | 413.69% |
| 2007 Q3 | 4.24 Million AUD | 440.83% |
| 2007 Q4 | -8.99 Million AUD | -312.04% |
| 2007 FY | - AUD | 111.07% |
| 2007 Q2 | -1.24 Million AUD | -145.93% |
| 2007 Q1 | 2.7 Million AUD | 119.52% |
| 2006 Q3 | 2.56 Million AUD | 1276.44% |
| 2006 Q4 | -13.87 Million AUD | -640.11% |
| 2006 Q1 | 3.37 Million AUD | 118.48% |
| 2006 FY | - AUD | 37.23% |
| 2006 Q2 | -218.37 Thousand AUD | -106.47% |
| 2005 FY | - AUD | 18.23% |
| 2005 Q4 | -18.26 Million AUD | -614.47% |
| 2005 Q1 | 3.76 Million AUD | 0.0% |
| 2005 Q2 | -153.78 Thousand AUD | -104.09% |
| 2005 Q3 | 3.55 Million AUD | 2409.12% |
| 2004 FY | - AUD | -803.49% |
| 2003 FY | - AUD | 82.41% |
| 2002 FY | - AUD | -13569.88% |
| 2001 FY | - AUD | 101.41% |
| 2000 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 94.649% |
| iSpecimen Inc. | -9.1 Million USD | -25.561% |
| Prenetics Global Limited | -47.89 Million USD | 76.134% |
| OpGen, Inc. | -29.51 Million USD | 61.266% |
| Exact Sciences Corporation | 41.87 Million USD | 127.297% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -577.576% |
| CareDx, Inc | -89.65 Million USD | 87.251% |
| Exagen Inc. | -19.15 Million USD | 40.319% |
| Inotiv, Inc. | -26.5 Million USD | 56.875% |
| Guardant Health, Inc. | -433.3 Million USD | 97.362% |
| Biodesix, Inc. | -37.1 Million USD | 69.192% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -359.958% |
| Precipio, Inc. | -4.31 Million USD | -164.722% |
| Aspira Women's Health Inc. | -16.49 Million USD | 30.685% |
| Standard BioTools Inc. | -54.45 Million USD | 79.01% |
| 23andMe Holding Co. | -291.87 Million USD | 96.084% |
| Castle Biosciences, Inc. | -45.02 Million USD | 74.612% |
| Personalis, Inc. | -96.8 Million USD | 88.192% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 90.277% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -19.181% |
| T2 Biosystems, Inc. | -43.87 Million USD | 73.947% |
| Neogen Corporation | 182.59 Million USD | 106.26% |
| Natera, Inc. | -383.27 Million USD | 97.018% |
| Myriad Genetics, Inc. | -67.8 Million USD | 83.141% |
| ICON Public Limited Company | 1.63 Billion USD | 100.701% |
| NeoGenomics, Inc. | -17.6 Million USD | 35.079% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -577.576% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 100.939% |
| RadNet, Inc. | 292.78 Million USD | 103.904% |
| MDxHealth SA | -30.46 Million USD | 62.483% |
| Check-Cap Ltd. | -17.64 Million USD | 35.233% |
| Twist Bioscience Corporation | -176.7 Million USD | 93.531% |
| Psychemedics Corporation | -251 Thousand USD | -4454.067% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 75.445% |
| Sera Prognostics, Inc. | -35.28 Million USD | 67.606% |
| OPKO Health, Inc. | -65.51 Million USD | 82.553% |
| Illumina, Inc. | -608 Million USD | 98.12% |
| DarioHealth Corp. | -53.49 Million USD | 78.632% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -16.821% |
| Medpace Holdings, Inc. | 363.15 Million USD | 103.148% |
| Prenetics Global Limited | -47.89 Million USD | 76.134% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -29.737% |
| Mainz Biomed B.V. | -25.01 Million USD | 54.298% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -49.826% |
| Trinity Biotech plc | -24.09 Million USD | 52.566% |
| Neuronetics, Inc. | -22.75 Million USD | 49.775% |
| Sotera Health Company | 514.14 Million USD | 102.223% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -49.826% |